Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00089024 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

A Phase 2 study, sponsored by University of Nebraska.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target

NCT00089024 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 29 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00089024, a Phase 2 study, has completed, sponsored by University of Nebraska.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with radiation therapy works in treating patients who may undergo surgery for locally advanced pancreatic cancer.

Interventions

  • DRUG oxaliplatin
  • DRUG fluorouracil
  • DRUG leucovorin calcium
  • PROCEDURE adjuvant therapy
  • DRUG gemcitabine hydrochloride

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2004-02-25
Est. Completion 2014-12-01
Phase Phase 2

Sponsor

University of Nebraska

407 total trials

What the Registry Record Tells You About NCT00089024

The ClinicalTrials.gov registry entry for NCT00089024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.

NCT00089024 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00089024 about?

NCT00089024 is a clinical study titled "Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so that it can be re...

What is the current status of trial NCT00089024?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2004-02-25. Estimated completion is 2014-12-01.

What interventions are being tested in trial NCT00089024?

The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), adjuvant therapy (PROCEDURE), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00089024?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.